1 |
|
Activation of NLRP3 inflammasome by SARS-CoV-2
|
7 |
2.035 |
SuperPathway |
- Activation of NLRP3 inflammasome by SARS-CoV-2
|
Pathways |
- Activation of NLRP3 inflammasome by SARS-CoV-2
|
Genes symbols |
|
|
2 |
|
Inflammasomes
|
32 |
1.265 |
|
3 |
|
Toll-Like receptor Signaling Pathways
|
133 |
0.535 |
|
4 |
|
Cellular responses to stimuli
|
802 |
0.535 |
|
5 |
|
Deubiquitination
|
298 |
0.535 |
|
6 |
|
Nucleotide-binding oligomerization domain (NOD) pathway
|
41 |
0.535 |
|
7 |
|
Metabolism of proteins
|
1970 |
0.535 |
|
8 |
|
SARS-CoV-1-host interactions
|
142 |
0.535 |
|
9 |
|
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
|
57 |
0.535 |
|
10 |
|
Nuclear events mediated by NFE2L2
|
199 |
0.535 |
|
11 |
|
Activation of NF-KappaB by PKR
|
51 |
0.535 |
|
12 |
|
Metalloprotease DUBs
|
37 |
0.535 |
|
13 |
|
SARS-CoV-2 mitochondrial chronic oxidative stress and endothelial dysfunction
|
17 |
0.535 |
|
14 |
|
Malignant pleural mesothelioma
|
409 |
0.535 |
|
15 |
|
SARS-CoV-2 Infection
|
414 |
0.535 |
|
16 |
|
Prostaglandin signaling
|
28 |
0.535 |
|
17 |
|
IL1 and megakaryocytes in obesity
|
24 |
0.535 |
|
18 |
|
Infectious disease
|
1747 |
0.535 |
|
19 |
|
Innate Immune System
|
2025 |
0.535 |
|
20 |
|
ADORA2B mediated anti-inflammatory cytokines production
|
419 |
0.535 |
|